Diversity of Humira biosimilar launches reveals the difficulty of dethroning AbbVie’s megablockbuster

Sandoz, Boehringer Ingelheim, Samsung and others are now taking their shot at AbbVie’s megablockbuster Humira, with launches of their biosimilars on Saturday, and myriad approaches to take market share that AbbVie has so far defended well against.

Boehringer, which is the only company with an interchangeable biosimilar on the market so far, confirmed that the lowest-cost version of its interchangeable won’t launch until next year, and the version that launched on July 1 is priced with only a slight discount to Humira.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

Heat shock protein protects bacteria from plasma treatment

A heat shock protein protects the cells against protein clumping. It degrades, however, over longer treatment periods.

November 24, 2023

Pliant shares spike on exploratory study results of lead drug in chronic liver disease

Pliant Therapeutics shared early-stage biomarker and imaging results, suggesting that patients with a chronic liver disease who received its drug had improved liver function compared

September 27, 2023

Heart attacks can be predicted with a standard blood test

Using the results of a standard blood test and an online tool, you can find out if you are at increased risk of having a

February 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.